Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$85.58 USD

85.58
407,379

-0.07 (-0.08%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $86.18 +0.60 (0.70%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (76 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Merit Medical's (MMSI) Latest Launch to Boost Patient Outcome

by Zacks Equity Research

Merit Medical's (MMSI) latest well-designed tray is expected to simplify the thoracostomy procedure and reduce treatment time, especially in critical situations.

Zacks Equity Research

Merit Medical's (MMSI) SCOUT Bx Delivery System Gets FDA Nod

by Zacks Equity Research

Merit Medical's (MMSI) receipt of FDA clearance for the SCOUT Bx system can streamline treatment for cancer patients.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Zacks Equity Research

Merit Medical's (MMSI) Product Included in FDA's Program

by Zacks Equity Research

Receipt of the Breakthrough Device Designation for Merit Medical's (MMSI) Embosphere Microspheres is expected to improve patient outcome.

Zacks Equity Research

Merit Medical's (MMSI) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in both its segments, and from majority of the product categories within its Cardiovascular unit.

Zacks Equity Research

Merit Medical (MMSI) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 42% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Merit Medical (MMSI) Q4 Earnings Expected to Decline

by Zacks Equity Research

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LabCorp (LH) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

LabCorp (LH) delivered earnings and revenue surprises of 14.75% and 2.95%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

McKesson (MCK) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

McKesson (MCK) delivered earnings and revenue surprises of 14.31% and 3.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its progress in the WAVE study and a strong product portfolio.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.

Zacks Equity Research

Merit Medical (MMSI) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Merit Medical's (MMSI) Q3 Earnings, Revenues Top Estimates

by Zacks Equity Research

Merit Medical (MMSI), in the third quarter, benefits from revenue growth in its Cardiovascular segment, and from the majority of the product categories within its Cardiovascular unit.

Zacks Equity Research

Merit Medical (MMSI) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 18.18% and 2.36%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Merit Medical (MMSI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

BDX or MMSI: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BDX vs. MMSI: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.

Zacks Equity Research

PDCO vs. MMSI: Which Stock Is the Better Value Option?

by Zacks Equity Research

PDCO vs. MMSI: Which Stock Is the Better Value Option?

Trina Mukherjee headshot

3 Promising MedTech Stocks to Snap Up in Second-Half 2021

by Trina Mukherjee

Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.

Zacks Equity Research

NextGen's (NXGN) New Partnership to Boost Patient Experience

by Zacks Equity Research

NextGen (NXGN) collaborates with Clinect Healthcare to extend patient-provider connection.

Zacks Equity Research

Veeva Systems' (VEEV) Cloud Applications Get Adopted by Emmes

by Zacks Equity Research

Veeva Systems' (VEEV) Development Cloud applications to aid in connected drug development.

Zacks Equity Research

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

Zacks Equity Research

Fresenius Medical's (FMS) Deal to Boost Home Dialysis in Japan

by Zacks Equity Research

Fresenius Medical (FMS) partners with JMS Co. Ltd. to provide innovative home dialysis therapies to the aging population in Japan to improve their wellbeing.

Zacks Equity Research

NextGen's (NXGN) New Collaboration to Boost Solutions Portfolio

by Zacks Equity Research

NextGen (NXGN) and Klamath partner to deliver large-scale COVID-19 vaccinations.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Align Technology, West Pharmaceutical Services, Henry Schein and Merit Medical Systems

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Align Technology, West Pharmaceutical Services, Henry Schein and Merit Medical Systems